

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

October 2016

A. GENERAL INFORMATION

1. Name **Alexia E. Iasonos, PhD**
2. Office address: Memorial Sloan-Kettering Cancer Center
485 Lexington Avenue, 2nd Floor
New York, NY 10017
- Office telephone: 646-888-8255
- Email: iasonosa@mskcc.org

B. EDUCATIONAL BACKGROUND

1. Degree(s):
- | <i>Degree</i> | <i>Institution name and location</i> | <i>Dates</i> | <i>Year Awarded</i> |
|------------------------------------|--------------------------------------|--------------|---------------------|
| BS,
Mathematics &
Statistics | University of Cyprus | 9/92-6/96 | 6/96 |
| MS, Biometry &
Statistics | SUNY Albany, Albany, NY | 9/96-5/98 | 6/98 |
| PhD, Biometry
& Statistics | SUNY Albany, Albany, NY | 8/99-5/02 | 5/02 |

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

1. Post-doctoral training including residency/fellowship: None
2. Academic positions

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Assistant Member, Level I	Memorial Sloan-Kettering Cancer Center New York, NY	3/05-4/08
Assistant Member	Memorial Sloan-Kettering Cancer Center New York, NY	4/08-5/13
Associate Member	Memorial Sloan-Kettering Cancer Center New York, NY	5/13-

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

3. Hospital positions

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Assistant Attending Biostatistician	Memorial Hospital for Cancer & Allied Diseases, New York, NY	3/05-5/13
Associate Attending Biostatistician	Memorial Hospital for Cancer & Allied Diseases, New York, NY	5/13 -

4. Other Employment

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Teacher Assistant	University at Albany, Albany, NY	9/96-6/97
Research Assistant	NY State Department of Health, Albany, NY	9/97-6/98
Senior Statistician	AC Nielsen, Nicosia, Cyprus	8/98-7/99
Teacher Assistant	University at Albany, Albany, NY	8/99-5/00
Research Assistant	NY State Department of Health, Albany, NY	5/00-11/00
Research Assistant	NY State Department of Labor, Albany, NY	11/00-8/01
Teacher Assistant	University at Albany, Albany, NY	9/01-7/02
Research Biostatistician	Bristol Myers Squibb, Wallingford, CT	8/02-3/05

D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

1. Licensure N/A
2. Board Certification N/A
3. Malpractice insurance N/A

E. PROFESSIONAL MEMBERSHIPS

<i>Member/officer</i>	<i>Name of Organization</i>	<i>Dates</i>
Member	American Statistical Association	2001-07, 2012 -
Member	American Society of Clinical Oncology (ASCO)	2006-
Member	Society of Clinical Trials	2009-
Member	International Society of Clinical Biostatistics	2011-

F. HONORS AND AWARDS

<i>Name of award</i>	<i>Date awarded</i>
Best Presentation Award, Albany Chapter American Statistical Association (ASA) Conference	2001
Best Paper Award, Albany Chapter ASA Conference	2001
Pharmaceutical Research Institute Star Award, Bristol Myers Squibb	2003
Awarded competitive admission to the Association of American Medical Colleges (AAMC) Mid-Career Women Faculty Professional Development Seminar in Austin, TX	2015

G. INSTITUTIONAL/HOSPITAL AFFILIATION

Primary Hospital Affiliation: **Memorial Hospital for Cancer and Allied Diseases**
 Other Hospital Affiliations: None
 Other Institutional Affiliations: None

H. EMPLOYMENT STATUS

Name of Employer(s): Memorial Sloan-Kettering Cancer Center
 Employment Status: Full-time salaried

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND EFFORT**1. Teaching/Mentoring (e.g., specific teaching and mentoring activities, courses taught, dates)**

<i>Activity</i>	<i>Dates</i>
<i>MSKCC invited seminars presented:</i>	
Continual Reassessment Method: simulations comparing four methods, Phase I Working Group	2007
A review of Phase I designs in oncology: a comprehensive comparison of the Continual Reassessment Method with the standard 3+3 dose escalation scheme. Biostatistics Forum, Weill Cornell Medical College	2007

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

Implementation of the continual reassessment method at MSKCC, Phase I Working Group 2008

A comparison of the continual reassessment method with the standard up and down design, MSKCC Experimental Therapeutics Center Retreat 2009

Estimating the dose-toxicity curve from completed Phase I studies, Phase I Working Group 2009

Introduction to Biostatistics, Gynecologic Fellows 2010

Clinical trial design, Gynecology Service Conference 2014

Statistical analyses for retrospective reviews, Gynecology Service Conference, Fellows Didactic Lecture 2014

Clinical trial design, Radiation Oncology, Fellows Lecture 2014

2. Clinical Care N/A

3. Administrative duties

<i>Activity</i>	<i>Dates</i>
Data and Safety Monitoring Committee for Phase I & II Trials	3/06- 3/12
Junior Faculty Council	10/07-9/09
Phase I Working Group	1/07- 1/13
Developmental Therapeutic Center	1/13-
Research Council	3/12-
Biostatistics Faculty Search Committee, Chair	8/13-7/14
Biostatistics Faculty Search Committee	2/15-7/15

4. Research

My methodological research interest is in the design and analysis of clinical trials, with a focus in Phase I Bayesian adaptive designs. Through my collaborations with the Gynecological Oncology group I am exploring various biomarkers and assessing relationships to histology, distant metastasis and clinical outcome. I am heavily involved in vaccine trials as a second line or maintenance therapy with the focus in identifying valid endpoints for ovarian cancer patients, as part of the Ovarian Program Project. In addition, I am working with surgeons in building predictive models and nomograms in gynecologic cancers.

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

	<u>Current Percent Effort (%)</u>	<u>Does the activity involve WMC students or researchers? (Y/N)</u>	<u>Does the activity involve MSK trainees or researchers? (Y/N)</u>
Teaching/Mentoring	5%	N	Y
Clinical Care	0%	N/A	N/A
Administration	15%	N	Y
Research	80%	N	Y
TOTAL	100%		

J. RESEARCH SUPPORT

Current:

Extramural research support:

“Epithelial Ovarian Cancer Program Project”

PO1 NIH CA190174

Amount: \$862,654 (\$79,025 for the Core)

Dates: 9/1/2015-8/31/2020

PI: David Spriggs

Role: Core PI, 20% effort

“Designs for phase I trials of combinations of agents”

R01 NIH# CA142859-04A1

Amount: \$21,602

Dates: 5/1/2014-4/30/2018

PI: Mark Conaway

Role: Subcontract PI, 10% effort

“Cancer Center Support Grant”

P30 NIH # CA008748

Amount: \$525,481

Dates: 1/1/2014-12/31/2018

PI: Colin Begg

Role: Co-Investigator, 5% effort

“The Genomic and Immune Landscape Following Neoadjuvant Chemotherapy in Ovarian Cancer”

Kaleidoscope of Hope Foundation

Amount: \$50,000

Dates: 5/1/2016 - 4/30/2017

PI: Snyder Charen

Role: Co-Investigator, 3% effort

“Unmasking Ovarian Cancers to Induce Immune Control”

Kaleidoscope of Hope Foundation

Amount: \$136,364

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

Dates: 2/1/2016 - 1/31/2019

PI: Snyder Charen

Role: Co-Investigator, 5% effort

“Novel approaches to locoregional and systemic immunotherapy for ovarian cancer”

Congressionally Directed Medical Research Programs: W81XWH-16-1-0298

Amount: \$144,885

Dates: 9/30/2016 – 9/29/2021

PI: Zamarin

Role: Co-Investigator, 5% effort

Intramural research support:

Surgery Research and Development Fund, MSKCC

Dates: 1/1/15 - 12/31/2015

Role: Co-Investigator, 35% effort

Completed:

Experimental Therapeutic Center, MSKCC

Amount: \$125,000

Dates: 1/1/15-12/31/2015

Role: Co-Investigator, 5% effort

“Personalizing Phase I dose finding studies: taking into account individual patient risk”

Translational and Integrative Medicine Research Fund (TIMRF)

Amount: \$65,000

Dates: 4/1/2014-3/31/2015

PI: Alexia Iasonos

Role: Principal Investigator, 20% effort

“Designs for phase I trials of combinations of agents”

R01 NIH# CA142859-01A1

Amount: \$ 296,402

Dates: 7/1/11-6/30/13

PI: Mark Conaway

Role: Subcontract PI, 10% effort

“Early Clinical Trials of New anti-cancer agents with Phase I emphasis”

U01 NIH # CA069856-16

Amount: \$ 258,850

Dates: 4/14/08-2/28/13

PI: David Spriggs

Role: Co-Investigator, 10% effort

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

“Targeting the P13K pathway in women’s cancers”

American Association of Cancer Research, SU2C-AACR-DT0209 (PI Sawyers)

Amount: \$950,000

Dates: 11/1/09-10/31/14

PI: Charles Sawyers

Role: Co-Investigator, 25% effort

“A Phase II Trial of Adjuvant WT1 Analog Peptide Vaccine in Patients with Recurrent Epithelial Ovarian Cancer who are in Second or Third Remission”

MSKCC Society

Dates: 7/1/12-6/30/13

PI: Roisin O'Cearbhaill

Role: Co-Investigator, 5% effort

“Assessing the continual reassessment method as a phase I design by comparing it to the standard dose escalation scheme”

Experimental Therapeutic Center at Memorial Sloan Kettering Cancer Center

Amount: \$50,000 (Year 1), \$70,000 (Year 2)

Dates: 7/1/07-7/1/09

PI: Alexia Iasonos PhD

Role: PI, 40% effort

The Byrne Foundation

Amount: \$320,000

Dates: 1/1/06-12/31/07

PI: George Bosl

Role: Co-Investigator, 20% effort

“Novel Approaches to Ovarian Cancer Treatment”

P20 OCRF-CA-01

Amount: \$225,000

Dates: 12/31/04-12/30/07

PI: Carol Aghajanian

Role: Co-Investigator, 15% effort

“Epithelial Ovarian Cancer Program Project”

PO1 NIH # CA 52477-13A3

Amount: \$1,111,409

Dates: 4/1/05-3/31/10

PI: David Spriggs

Role: Core Co-PI, 40% effort

PO1 CA05826-38, NIH/ NCI

Amount: \$203,888

Dates: 12/1/02 –11/30/05

PI: George Bosl; Biostat Core PI: Colin Begg

Role: Investigator, 10% effort

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

International Activities:

International Workshop in the Statistical Design of Phase I Studies, Organizer & Chair, 2009

Symposium on early phase dose finding methodology, Scientific and Organizing Committee, 2014-2015

National & Regional Activities:

American Statistical Association, Education Committee Chair, Connecticut Chapter, 2003-2005

American Statistical Association, Treasurer (elected), Connecticut Chapter, 2004-2005

Susan G. Komen for the Cure, Scientific Reviewer, 2008-2011

Caucus for Women in Statistics, Representative (elected), 2008-2009

ASCO Program Committee, Biostatistics Track, Reviewer, 2009- 2012

Special Issue in Statistics in Medicine in Phase I Design, Guest Editor, 2010

Special Issue in Statistics in Medicine: Proceedings from ISCB meeting, Associate Editor, 2012

International Society of Clinical Biostatistics, Membership Committee, 2012-

Conquer Cancer Foundation of ASCO Grants Selection Committee, Member, 2012-

Society of Clinical Trials, Preconference Workshop Instructor, 2013

International Society of Clinical Biostatistics, Preconference Workshop Instructor, 2013

NCI Ovarian Task Force, Elected Member, 2014 -

NCI Gynecologic Cancer Steering Committee, Elected member, 2014 –

NCI, Working group of evaluating dose expansion cohorts, 2014 - 2015

Journal of Clinical Oncology, Editorial board, Member, 2014 –

Roche, Scientific Forum, 2015

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

ENAR, Preconference Workshop Instructor, 2015

Clinical Trials, Associate Editor, 2015-

Journal of the National Cancer Institute, Statistical Reviewer 2015-

Special Issue in Statistics in Medicine in Phase I Designs, Associate Editor, 2015 – 2016

AACR, Chairperson of the Biostatistics in Clinical Trials Section, 2016

Joint Statistical Meeting, Preconference Workshop Instructor, 2016

Invited Seminars Presented:

Albany Chapter American Statistical Association Meeting, NY, 2001

Albany Chapter American Statistical Association Meeting, NY, 2002

Weill Cornell Medical College, Biostatistics Seminar, NY, 2007

University of Pennsylvania, Biostatistics Seminar, Philadelphia, PA, 2009

Baruch College, City University of New York, Biostatistics Seminar, New York, NY, 2009

University of Reading, Workshop on dose-finding methodology in early phase clinical trials, UK, 2010

University of California San Francisco, Biostatistics Seminar, CA, 2011

Université Paris 6, Second workshop on dose-finding methodology in early phase clinical trials, France, 2011.

Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, NJ, 2011.

The University of Texas MD Anderson Texas Cancer Center, TX, 2012.

Joint Statistical Meeting, San Diego, CA, 2012

University of Virginia, Charlottesville, VA, 2012

Yale University, New Haven, CT, 2012

Mount Sinai Hospital, New York, NY, 2013

Joint Statistical Meeting, Montreal, Canada, 2013

Third workshop on dose-finding methodology in early phase clinical trials, Ann Arbor, Michigan, 2013

Symposium on early phase dose finding methodology, Paris, France, 2015

The Fifth International Workshop in Sequential Methodologies, New York, NY 2015

Eastern North American Region, International Biometric Society, Miami, FL, 2015

American Association for Cancer Research Meeting, New Orleans, LA, 2016

Joint Statistical Meeting, Chicago, IL, 2016

International Chinese Statistical Association, Atlanta, GA, 2016

Society for Clinical Trials Meeting, Montreal, Quebec, Canada, 2016

Symposium on Pharmacogenetic Epidemiology, New York, NY, 2016

Journal review:

Journal of Clinical Oncology; Clinical Cancer Research, International Journal of Gynecological Cancer,

Journal of the National Cancer Institute, Clinical Trials; Controlled Clinical Trials

Statistics in Medicine; Biometrics

L. BIBLIOGRAPHY

1. Peer-Reviewed Articles

1. Raj GV, **Iasonos A**, Herr H, Donat MS, Formulas Calculating Creatinine Clearance Are Inadequate For Determining Eligibility For Cisplatin-Based Chemotherapy In Bladder Cancer. J Clin Oncol 2006; 24:3095-100.
2. Abu-Rustum N, Alektiar K, **Iasonos A**, Lev G, Sonoda Y, Aghajanian C, Chi DS, Barakat RR. The Incidence of Symptomatic Lower-Extremity Lymphedema Following Treatment of Uterine Corpus Malignancies: An 11-Year Experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006;103(2):714-8.
3. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, **Iasonos A**, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K. Phase I Study of the Anti-Idiotypic Monoclonal Antibody Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Clin Cancer Res 2006; 12:5503-10.

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

4. Juretzka MM, Barakat RR, Chi DS, **Iasonos A**, et al. CA125 Level as a Predictor of Progression Free Survival and Overall Survival in Ovarian Cancer Patients with Surgically Defined Disease Status at the End of Primary Therapy. *Gynecol Oncol* 2007; 104:176-80.
5. Raj GV, Bach AM, **Iasonos A**, Korets R, Blitstein J, Hann L, Russo P Predicting the histology of renal masses using pre-operative doppler ultrasonography. *Journal of Urology* 2007; 177:53-8.
6. Diefenbach CSM., Soslow RA, **Iasonos A**, Hedvat C, Bonham L, Singer J, Barakat R., Aghajanian C., Dupont J. Lysophosphatidic Acid Transferase-Beta (LPAAT- β) is Highly Expressed in Advanced Ovarian Cancer and is Associated with Aggressive Histology, Distant Metastases and Poor Survival. *Cancer* 2006; 107:1511-9.
7. Diefenbach CSM, Shah Z, **Iasonos A**, Barakat RR et al. Pre-operative serum YKL-40 is a serum marker for detection and prognosis of endometrial cancer. *Gynecol Oncol* 2007; 104:435-42.
8. Sabbatini P, Mooney D, **Iasonos A**, Thaler H, Aghajanian C, Hensley M, Tew W, Konner J, Spriggs D, Abu-Rustum N, Dupont J. CA-125 Patterns in Recurrent Ovarian Cancer treated with Carboplatin, Liposomal Doxorubicin, or Topotecan. *Int J Gynecol Cancer* 2007; 17:589-94.
9. Basch E, **Iasonos A**; McDonough T, Barz A; Culkin A RN; Kris M; Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). *The Lancet Oncology* 2006; 7:903-9.
10. Galsky MD, **Iasonos A**, Mironov S, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. *Cancer* 2007; 109:549-55.
11. Galsky MD, Mironov S, **Iasonos A**, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. *Invest New Drugs* 2007; 25:265-70.
12. Basch E, Artz D, Speakman J, **Iasonos A**, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher HI, McCabe M, Schrag D. Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. *J Am Med Inform Assoc* 2007; 14:264-8.
13. Dos Santos L, Mok E, **Iasonos A**, Park K, Soslow RA, Aghajanian C, Alektiar K, Barakat RR, Abu-Rustum NR. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: A case series and review of the literature. *Gynecol Oncol* 2007; 105:321-4.
14. Sabbatini P, Ragupathi G, Hood C, Aghajanian C, Juretzka M, **Iasonos A**, Hensley M, Spriggs D, Tew W, Konner J, Clausen H, Rustum NA, Dansiehefsky S, Livingston P. Pilot study of a heptavalent vaccine-KLH conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. *Clin Cancer Res* 2007; 13:4170-7.
15. Galsky MD, **Iasonos A**, Mironov S, Scattergood J, Donat SM, Bochner BH, Herr HW, Russo P, Boyle MG, Bajorin DF. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. *Urology* 2007; 69:255-9.

16. Harrison ML, Gore ME, Spriggs D, Kaye S, **Iasonos A**, Hensley M, Aghajanian C, Venkatraman E, Sabbatini P. Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials. *Gynecol Oncol* 2007; 106:469-75.
17. Black D, **Iasonos A**, Ahmed H, Chi DS, Barakat RR, Abu-Rustum NR. Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer. *Gynecol Oncol* 2007; 107:66-70.
18. Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, **Iasonos A**, Sabbatini P. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. *Cancer* 2007; 110:2458-66.
19. Basch E, **Iasonos A**, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schrag D. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. *J Clin Oncol* 2007 Dec 1;25(34):5374-80.
20. Juretzka M, Hensley ML, Tew W, Konner J, Aghajanian C, Leitao M, **Iasonos A**, Soslow R, Park K, Sabbatini P. A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. *Eur J Gynaecol Oncol*. 2008;29(6):568-72.
21. **Iasonos A**, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. *Clin Trials* 2008;5(5):465-77. PMID: PMC2637378.
22. Zivanovic O, Eisenhauer EL, Zhou Q, **Iasonos A**, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. *Gynecol Oncol*. 2008;108(2):287-92.
23. Caceres A, Zhou Q, **Iasonos A**, Gerdes H, Chi DS, Barakat RR. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. *Gynecol Oncol*. 2008 Mar;108(3):482-5.
24. **Iasonos A**, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol*. 2008;26(8):1364-70. Review.
25. Black D, Levine DA, Nicoll L, Chou JF, **Iasonos A**, Brown CL, Sonoda Y, Chi DS, Leitao MM, Abu-Rustum NR, Ferguson SE, Barakat RR. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. *Gynecol Oncol*. 2008;109(1):39-42.
26. Abu-Rustum NR, **Iasonos A**, Zhou Q, Oke E, Soslow RA, Alektiar KM, Chi DS, Barakat RR. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? *Am J Obstet Gynecol*. 2008;198(4):457.e1-5; discussion 457.e5-6.

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

27. Diefenbach CS, Gnjjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, **Iasonos A**, Lee H, Dupont B, Pezzulli S, Jungbluth AA, Old LJ, Dupont J. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. *Clin Cancer Res*. 2008;14(9):2740-8.
28. Thompson RH, Ordonez MA, **Iasonos A**, Secin FP, Guillonneau B, Russo P, Touijer K. Renal cell carcinoma in young and old patients--is there a difference? *J Urol*. 2008;180(4):1262-6; discussion 1266. PMID: PMC2615196.
29. Makker V, Abu-Rustum NR, Alektiar KM, Aghajanian CA, Zhou Q, **Iasonos A**, Hensley ML. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. *Gynecol Oncol*. 2008;111(2):249-54.
30. Zivanovic O, Alektiar KM, Sonoda Y, Zhou Q, **Iasonos A**, Tew WP, Diaz JP, Chi DS, Barakat RR, Abu-Rustum NR. Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. *Gynecol Oncol*. 2008;111(2):265-70.
31. Zivanovic O, Leitao MM, **Iasonos A**, Jacks LM, Zhou Q, Abu-Rustum NR, Soslow RA, Juretzka MM, Chi DS, Barakat RR, Brennan MF, Hensley ML. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. *J Clin Oncol*. 2009;27(12):2066-72.
32. Milowsky MI, Nanus DM, Maluf FC, Mironov S, Shi W, **Iasonos A**, Riches J, Regazzi A, Bajorin DF. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. *J Clin Oncol*. 2009;27(25):4062-7.
33. Zivanovic O, Sima CS, **Iasonos A**, Bell-McGuinn KM, Sabbatini PJ, Leitao MM, Levine DA, Gardner GJ, Barakat RR, Chi DS. Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. *Gynecol Oncol*. 2009;115(2):209-14.
34. Gallagher DJ, Milowsky MI, **Iasonos A**, Maluf FC, Russo P, Dalbagni G, Donat MS, Boyle MG, Zheng J, Riches J, Bajorin DF. Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. *Cancer*. 2009;115(22):5193-201.
35. O'Cearbhaill R, Zhou Q, **Iasonos A**, Soslow RA, Leitao MM, Aghajanian C, Hensley ML. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. *Gynecol Oncol*. 2010;116(3):424-9.
36. O'Cearbhaill R, Zhou Q, **Iasonos A**, Hensley ML, Tew WP, Aghajanian C, Spriggs DR, Lichtman SM, Sabbatini PJ. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. *Gynecol Oncol*. 2010;116(3):326-31.
37. Garg K, Shih K, Barakat R, Zhou Q, **Iasonos A**, Soslow RA. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. *Am J Surg Pathol*. 2009;33(12):1869-77.

38. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, **Iasonos A**, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. *J Natl Cancer Inst.* 2009;101(23):1624-32. PMID: PMC2786917.
39. Sabbatini P, Spriggs D, Aghajanian C, Hensley M, Tew W, Konner J, Bell-McGuinn K, Juretzka M, **Iasonos A**. Consolidation strategies in ovarian cancer: observations for future clinical trials. *Gynecol Oncol.* 2010;116(1):66-71.
40. Abu-Rustum NR, Zhou Q, Gomez JD, Alektiar KM, Hensley ML, Soslow RA, Levine DA, Chi DS, Barakat RR, **Iasonos A**. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. *Gynecol Oncol.* 2010;116(3):399-403.
41. Carter J, Sonoda Y, Baser RE, Raviv L, Chi DS, Barakat RR, **Iasonos A**, Brown CL, Abu-Rustum NR. A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. *Gynecol Oncol.* 2010;119(2):358-65. PubMed PMID: 20817227.
42. Shih KK, Zhou QC, Aghajanian C, Huh J, Soslow RA, Morgan JC, **Iasonos A**, Chi DS, Barakat RR, Abu-Rustum NR. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. *Gynecol Oncol.* 2010;119(2):270-3. PubMed PMID: 20719369.
43. Fu M, Maresh EL, Soslow RA, Alavi M, Mah V, Zhou Q, **Iasonos A**, Goodglick L, Gordon LK, Braun J, Wadehra M. Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer. *Clin Cancer Res.* 2010;16(15):3954-63. PubMed PMID: 20670949; PubMed Central PMCID: PMC2913478.
44. Dharma Rao T, Park KJ, Smith-Jones P, **Iasonos A**, Linkov I, Soslow RA, Spriggs DR. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. *Appl Immunohistochem Mol Morphol.* 2010;18(5):462-72. PubMed PMID: 20453816.
45. Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, **Iasonos A**, Portlock CS, Straus D, Noy A, Palomba ML, O'Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. *J Clin Oncol.* 2010;28(11):1896-903. PubMed PMID: 20212248.
46. Carter J, Raviv L, Appollo K, Baser RE, **Iasonos A**, Barakat RR. A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors. *Gynecol Oncol.* 2010;117(2):317-23. PubMed PMID: 20163847.
47. Zivanovic O, Sima CS, **Iasonos A**, Hoskins WJ, Pingle PR, Leitao MM Jr, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS. The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. *Gynecol Oncol.* 2010;116(3):351-7. PubMed PMID: 20022092.

48. Shih KK, Zhou Q, Huh J, Morgan JC, **Iasonos A**, Aghajanian C, Chi DS, Barakat RR, Abu-Rustum NR. Risk factors for recurrence of ovarian borderline tumors. *Gynecol Oncol*. 2011;120(3):480-4. PubMed PMID: 21146201.
49. **Iasonos A**, Ostrovnaya I. Estimating the dose-toxicity curve in completed phase I studies. *Statistics in Medicine* 2011;30(17):2117-29.
50. Gerecitano J, Portlock C, Hamlin P, Moskowitz CH, Noy A, Straus D, Schulman P, Dumitrescu O, Sarasohn D, Pappanicholaou J, **Iasonos A**, Zhang Z, Mo Q, Horanlli E, Rojas CN, Zelenetz AD, O'Connor OA. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. *Clin Cancer Res*. 2011;17(8):2493-501.
51. Abu-Rustum NR, Zhou Q, **Iasonos A**, Alektiar KM, Leitao MM Jr, Chi DS, Sonoda Y, Soslow R, Hensley M, Barakat RR. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? *Int J Gynecol Cancer*. 2011;21(3):511-6.
52. Zivanovic O, Jacks LM, **Iasonos A**, Leitao MM Jr, Soslow RA, Veras E, Chi DS, Abu-Rustum NR, Barakat RR, Brennan MF, Hensley ML. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. *Cancer* 2012;118(3):660-9.
53. **Iasonos A**, Zohar S, O'Quigley J. Incorporating lower grade toxicity information into dose finding designs. *Clin Trials* 2011;8(4):370-9.
54. Hyman DM, Zhou Q, Arnold AG, Grisham RN, **Iasonos A**, Kauff ND, Spriggs D. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. *Gynecol Oncol*. 2011;123(2):196-9.
55. Hensley ML, Kravetz S, Jia X, **Iasonos A**, Tew W, Pereira L, Sabbatini P, Whalen C, Aghajanian CA, Zarwan C, Berlin S. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study. *Cancer* 2012;118(9):2403-10.
56. **Iasonos A**, Sabbatini P, Spriggs DR, Aghajanian CA, O'Cearbhaill RE, Hensley ML, Thaler HT. Identifying clinical improvement in consolidation single-arm phase II trials in patients with ovarian cancer in second or greater clinical remission. *Int J Gynecol Cancer* 2012;22(1):63-9.
57. Konner JA, Grabon DM, Gerst SR, **Iasonos A**, Thaler H, Pezzulli SD, Sabbatini PJ, Bell-McGuinn KM, Tew WP, Hensley ML, Spriggs DR, Aghajanian CA. A Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal Stage II/III epithelial ovarian cancer. *J Clin Oncol*. 2011;29(35):4662-8.
58. Hyman D, Zhou Q, **Iasonos A**, Grisham R, Arnold AG, Phillips MF, Bhatia J, Levine D, Aghajanian C, Barakta RR, Spriggs DR, Kauff ND. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. *Cancer* 2012;118(15):3703-9.
59. Polterauer S, Zhou Q, Grimm C, Seebacher V, Reinthaller A, Hofstetter G, Concin N, Leitao MM,

- Barakat RR, Abu-Rustum NR, **Iasonos A**. External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. *Gyn Oncology* 2012;125(3):526-30.
60. Tanner EJ, Long KC, Zhou Q, Brightwell RM, Gardner GJ, Abu-Rustum NR, Leitao MM Jr, Sonoda Y, Barakat RR, **Iasonos A**, Chi DS. Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. *Gynecol Oncol.* 2012;125(3):526-30.
61. Grisham RN, Adaniel C, Hyman DM, Ma W, **Iasonos A**, Aghajanian C, Konner J. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial Sloan-Kettering Cancer Center experience. *Int J Gynecol Cancer.* 2012;22(5):807-11.
62. **Iasonos A.**, O'Quigley J. Interplay of priors and skeletons in two-stage continual reassessment method. *Statistics in Medicine* 2012;31(30):4321-36.
63. **Iasonos A**, Mrinal Gounder M, Spriggs DR, Gerecitano JF, Hyman DM, Zohar S, O'Quigley J. The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. *Clinical Cancer Research* 2012;18(19):5179-87.
64. Grisham RN, Iyer G, Garg K, Delair D, Hyman DM, Zhou Q, **Iasonos A**, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB. BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. *Cancer.* 2013;119(3):548-54.
65. Balar AV, Apolo A, Ostrovnaya I, Mironov S, **Iasonos A**, Trout A, Regazzi AM, Garcia-Grossman IR, Gallagher DJ, Milowsky MI, Bajorin DF. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. *J Clin Oncol.* 2013 Feb 20;31(6):724-30.
66. Apolo AB, Ostrovnaya I, Halabi S, **Iasonos A**, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. *J Natl Cancer Inst.* 2013 Apr 3;105(7):499-503. PMCID: PMC3691944.
67. **Iasonos A**, Keung EZ, Zivanovic O, Mancari R, Peiretti M, Nucci M, George S, Colombo N, Carinelli S, Hensley ML, Raut CP. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. *Cancer.* 2013 May 15;119(10):1816-22. PubMed PMID: 23456762; PubMed Central PMCID: PMC4044863.
68. Makker V, Hensley ML, Zhou Q, **Iasonos A**, Aghajanian CA. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009. *Int J Gynecol Cancer.* 2013 Jun;23(5):929-34. PubMed PMID: 23598889; PubMed Central PMCID: PMC3694716.
69. Barlin JN, Zhou Q, St Clair CM, **Iasonos A**, Soslow RA, Alektiar KM, Hensley ML, Leitao MM Jr, Barakat RR, Abu-Rustum NR. Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. *Gynecol Oncol.* 2013 Sep;130(3):452-6. PMCID: PMC3748179.

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

70. Makker V, Kravetz SJ, Gallagher J, Orodol OP, Zhou Q, **Iasonos A**, DeLair D, Aghajanian C, Hensley ML. Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation. *Int J Gynecol Cancer*. 2013 Nov;23(9):1635-41. PubMed PMID: 24172099.
71. Barlin JN, Soslow RA, Lutz M, Zhou QC, St Clair CM, Leitao MM Jr, **Iasonos A**, Hensley ML, Barakat RR, Matias-Guiu X, Abu-Rustum NR. Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment. *Int J Gynecol Cancer*. 2013 Nov;23(9):1620-8. PubMed PMID: 24126219.
72. Barlin JN, Soslow RA, Lutz M, Zhou QC, St Clair CM, Leitao MM Jr, **Iasonos A**, Hensley ML, Barakat RR, Matias-Guiu X, Abu-Rustum NR. Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment. *Int J Gynecol Cancer*. 2013 Nov;23(9):1620-8. PubMed PMID: 24126219.
73. **Iasonos A**, O'Quigley J. Design considerations for dose-expansion cohorts in phase I trials. *J Clin Oncol*. 2013 Nov 1;31(31):4014-21. PubMed PMID: 24101039.
74. Hyman DM, Eaton AA, Gounder MM, Smith GL, Pamer EG, Hensley ML, Spriggs DR, Ivy P, **Iasonos A**. Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. *J Clin Oncol*. 2014 Feb 20;32(6):519-26. PubMed PMID: 24419130; PMCID: PMC3918535.
75. O'Quigley J, **Iasonos A**. Bridging Solutions in Dose Finding Problems. *Stat Biopharm Res*. 2014 May 1;6(2):185-197. PubMed PMID: 25071878; PubMed Central PMCID: PMC4111208.
76. Grisham RN, Iyer G, Sala E, Zhou Q, **Iasonos A**, DeLair D, Hyman DM, Aghajanian C. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. *Int J Gynecol Cancer*. 2014 Jul;24(6):1010-4. PubMed PMID: 24978709.
77. Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, **Iasonos A**, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. *Gynecol Oncol*. 2014 Sep;134(3):455-61. PubMed PMID: 25019568.
78. Hyman DM, Eaton AA, Gounder MM, Ivy SP, **Iasonos A**, Spriggs DR. Reply to M. Voskoboynik et al. *J Clin Oncol*. 2014 Oct 1;32(28):3199-200. PMID: 25071117.
79. Meisel JL, Hyman DM, Garg K, Zhou Q, Dao F, Bisogna M, Gao J, Schultz ND, Grisham RN, Phillips M, **Iasonos A**, Kauff ND, Levine DA, Soslow RA, Spriggs DR. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. *Ann Oncol*. 2014 Dec;25(12):2372-8. PubMed PMID: 25281711.
80. Meisel J, Hyman D, Jotwani A, Zhou Q, Abu-Rustum NR, **Iasonos A**, Pike MC, Aghajanian C. The Role of Systemic Chemotherapy in the Management of Granulosa Cell Tumors. *Gyn Oncology*. In press 2015.

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

81. Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, **Iasonos A**, Spriggs DR, Bialer P, Lacouture ME, Teitcher JB, Katabi N, Fury MG. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2015 Apr;75(4):747-55.
82. Suidan RS, Zhou Q, **Iasonos A**, O'Cearbhaill RE, Chi DS, Long Roche KC, Tanner EJ, Denesopolis J, Barakat RR, Zivanovic O. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer. *Int J Gynecol Cancer*. 2015 May;25(4):599-606.
83. Korc-Grodzicki B, Sun SW, Zhou Q, **Iasonos A**, Lu B, Root JC, Downey RJ, Tew WP. Geriatric Assessment as a Predictor of Delirium and Other Outcomes in Elderly Patients With Cancer. *Ann Surg*. 2015 Jun;261(6):1085-90. PubMed PMID: 24887981.
84. **Iasonos A.**, Gonen M., Bosl G. Scientific review of Phase I protocols with novel dose escalation designs: how much information is needed? *Journal of Clinical Oncology*. 2015 Jul 1;33(19):2221-5.
85. Hyman DM, Eaton AA, Gounder MM, Pamer EG, Pettiford J, Carvajal RD, Ivy SP, **Iasonos A**, Spriggs DR. Predictors of Early Treatment Discontinuation in Patients Enrolled on Phase I Oncology Trials. *Oncotarget*. 2015 Aug 7;6(22):19316-27.
86. Iasonos A, O'Quigley J. Clinical trials: Early phase clinical trials-are dose expansion cohorts needed? *Nat Rev Clin Oncol*. 2015 Nov;12(11):626-8.
87. Satagopan J, **Iasonos A**, Zhou Q. Prognostic and predictive values of statistical interactions in the era of personalized medicine. *Genet Epidemiol*. 2015 Nov;39(7):509-17.
88. Shu CA, Zhou Q, Jotwani AR, **Iasonos A**, Leitao MM Jr, Konner JA, Aghajanian CA. Ovarian clear cell carcinoma, outcomes by stage: The MSK experience. *Gynecol Oncol*. 2015 Nov;139(2):236-41.
89. Schiavone MB, Zivanovic O, Zhou Q, Leitao MM Jr, Levine DA, Soslow RA, Alektiar KM, Makker V, **Iasonos A**, Abu-Rustum NR. Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. *Ann Surg Oncol*. 2016 Jan;23(1):196-202.
90. **Iasonos A** and O'Quigley J. Dose expansion cohorts in Phase I trials. *Stat Biopharm Res*. 2016;8(2):161-170.
91. Eaton A, **Iasonos A**, Gounder, et al. Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities. *Clin Cancer Res*. 2016 Feb 1;22(3):553-9.
92. Bell-McGuinn KM, Konner JA, Tew WP, Hensley ML, **Iasonos A**, Charpentier E, Mironov S, Sabbatini P, Aghajanian C. A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. *Int J Gynecol Cancer*. 2016 Feb;26(2):255-60.

93. **Iasonos A** and O'Quigley J. Sequential Monitoring of Phase I Dose expansion cohorts. *Stat Med*. 2016 Feb 7. doi: 10.1002/sim.6894. [Epub ahead of print]
94. Mueller JJ, Zhou QC, **Iasonos A**, O'Cearbhaill RE, Alvi FA, El Haraki A, Eriksson AG, Gardner GJ, Sonoda Y, Levine DA, Aghajanian C, Chi DS, Abu-Rustum NR, Zivanovic O. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. *Gynecol Oncol*. 2016 Mar;140(3):436-42.
95. Liang LW, Perez AR, Cangemi NA, Zhou Q, **Iasonos A**, Abu-Rustum N, Alektiar KM, Makker V. An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma. *Int J Gynecol Cancer*. 2016 Mar;26(3):497-504.
96. Hyman DM, Solit DB, **Iasonos A**. Reply to M.P. Decatris et al. *J Clin Oncol*. 2016 Mar 10;34(8):887.
97. Hyman DM, Eaton A, Ivy SP, Spriggs DR, **Iasonos A**. Measuring Toxicity in Phase I Clinical Trials-Letter. *Clin Cancer Res*. 2016 Apr 1;22(7):1828.
98. Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, **Iasonos A**, Lacouture ME, Hyman DM. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. *Cancer*. 2016 Apr 15;122(8):1228-37.
99. O'Cearbhaill RE, Ragupathi G, Zhu J, Wan Q, Mironov S, Yang G, Spassova MK, **Iasonos A**, Kravetz S, Ouerfelli O, Spriggs DR, Danishefsky SJ, Sabbatini PJ. A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission. *Cancers (Basel)*. 2016 Apr 22;8(4).
100. **Iasonos A**, Chapman PB, Satagopan JM. Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker. *Clin Cancer Res*. 2016 May 1;22(9):2114-20.
101. **Iasonos A**, O'Quigley J. Integrating the escalation and dose expansion studies into a unified Phase I clinical trial. *Contemp Clin Trials*. 2016 Sep;50:124-34.
102. **Iasonos A**, Wages NA, Conaway MR, Cheung K, Yuan Y, O'Quigley J. Dimension of model parameter space and operating characteristics in adaptive dose-finding studies. *Stat Med*. 2016 Sep 20;35(21):3760-75.
103. Mueller JJ, Kelly A, Zhou Q, **Iasonos A**, Long Roche K, Sonoda Y, O'Cearbhaill RE, Zivanovic O, Chi DS, Gardner GJ. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. *Gynecol Oncol*. 2016 Sep 28. pii: S0090-8258(16)31420-2.
104. **Iasonos A**, O'Quigley J. Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events. *Journal of the Royal Statistical Society: Series C (Applied Statistics)*. 2016 (in press).
2. Books, book chapters and reviews and editorials

1. **Iasonos A.** Statistics for the beginners in gynaecologic oncology. Textbook of Gynaecological Oncology, ESGO-ENYGO Endorsed. Gunes Tip Kitabevleri, 2009, p. 150.
2. **Iasonos A.**, O'Quigley J. Continual reassessment and related designs in dose finding studies. *Statistics in Medicine*. 2011 Jul 30;30(17):2057-61. Editorial.
3. O'Quigley J, **Iasonos A.** Dose finding designs based on the continual reassessment method. *Handbook of Statistics in Clinical Oncology* ed. by John Crowley and Marcel Dekker. 2011; 21-52.
4. **Iasonos A.** The Efficacy of Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer Patients and Its Effects On Patient-Reported Outcomes. *JCO* podcast. 2014 May 1;32 (13): 1302-1308.
5. **Iasonos A.** Disease-Free Survival among Ovarian Cancer Patients: Time in Remission Matters. *JCO* podcast. 2014 December 20; 32(36): 4102-4112
<http://jco.ascopubs.org/content/32/36/4102.full.pdf+html>
6. **Iasonos A**, O'Quigley J. Adaptive dose-finding studies: a review of model-guided phase I clinical trials. *J Clin Oncol*. 2014 Aug 10;32(23):2505-11. Epub 2014 Jun 30. PMID: PMC4121508.
7. **Iasonos A**, O'Quigley J. Early phase clinical trials- are dose expansion cohorts needed? *Nature Reviews Clinical Oncology*. 2015 Nov;12(11):626-8. doi: 10.1038/nrclinonc.2015.174. Epub 2015 Oct 6.
8. Hyman DM, Solit DB, **Iasonos A.** Reply to M. Decatris et al. *J Clin Oncol*. 2016 Jan 11. pii: JCO652487.
9. **Iasonos A**, O'Quigley J. Early Phase Dose Finding Methodology. *Statistics in Medicine*. 2016 (in press). Editorial.
10. Cunanan K, Gonen M, Shen R, Hyman DM, Riely G, Begg CB, **Iasonos A.** Basket trials in oncology: a trade-off between complexity and efficiency. *Journal of Clinical Oncology*. 2016 (in press)
11. Schram AM, Iasonos A, Hyman DM. Picking the Right Patient for Human Epidermal Growth Factor Receptor 3–Targeted Therapy in Platinum-Resistant Ovarian Cancer. *Journal of Clinical Oncology*. 2016 (in press)

3. Abstracts (up to 2012)

1. Abu-Rustum NR, Alektiar K, Lev G, **Iasonos A**, Sonoda Y, Aghajanian C, Barakat RR, ChiDS. The incidence of symptomatic lower extremity lymphedema following treatment of uterine corpus malignancies: An 11 year experience at Memorial Sloan-Kettering Cancer Center. Presented at the 2005 Society Gynecologic Oncology.
2. Persky D, Portlock CS, Lessac-Chenen S, **Iasonos A**, Zelenetz AD, Kewalramani T, Rice D, Yahalom J, Nimer SD, Moskowitz CH. The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL). Presented at the 2005 American Society Hematology.

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

3. Persky D, Teruya-Feldstein J, Kewalramani T, Bonner PD, **Iasonos A**, Rice D, Yahalom J, Nimer SD, Zelenetz AD, Moskowitz CH. High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin's Lymphoma. Presented at the 2005 American Society Hematology.
4. Galsky MD, **Iasonos A**, Mironov S, Scattergood J, Donat SM, Bochner Bochner BH, Her HW, Russo P, Boyle MG, Bajorin DF. Prospective trial of ifosfamide, paclitaxel, and cisplatin (ITP) in patients with advanced non-transitional cell (non-TCC) carcinomas of the urothelial tract. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4542
5. Basch EM, McDonough T, **Iasonos A**, Siegel E, Culkin A, Kris M, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 8515
6. Raj GV, **Iasonos A**, Bach A, Hann L, Russo P. Predicting the histology of renal masses using pre-operative Doppler ultrasonography. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4598.
7. Basch EM, Barz A, **Iasonos A**, Culkin A, Kris M, Speakman J, Artz D, Schrag D. Online reporting of toxicity symptoms by lung cancer patients during chemotherapy. Presented at the 2006 annual U.S. meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Philadelphia, PA.
8. Basch EM, **Iasonos A**, McDonough T, Barz A, Culkin A, Kris M, Scher HI, Schrag D. Patient and clinician symptom reporting using the CTCAE. Presented at the 2006 meeting, National Cancer Institute Patient Reported Outcomes Assessment in Cancer Trials (NCI PROACT), Bethesda, MD.
9. Basch EM, **Iasonos A**, Barz A, Culkin A, Kris M, Scher HI, Schrag D. Online symptom reporting by cancer patients. Presented at the 2006 11th World Congress on Internet in Medicine (Mednet), Toronto, Canada.
10. Abu-Rustum NR, Alektiar K, **Iasonos A**, Lev G, Sonoda Y, Aghajanian, Chi DS, Barakat RR. Surgical Removal of Pelvic Lymph Nodes Influences Endometrial Cancer Outcomes: An 11-Year Study. 2006 International Gynecologic Cancer Society Meeting, IGCS
11. Moss RA, Phillips MK, **Iasonos A**, Konner J. "CA125 Nadir and Religious Preference as Prognostic Markers in Ovarian Cancer". Presented at the Lynne Cohen Foundation for Ovarian Cancer Research Conference on The Emerging Role of Screening and Prevention in Women's Cancer, New York University, New York, NY, May 4-5, 2006
12. Ordonez M, Snyder M, **Iasonos A**, Secin F, Russo P, Guillonneau B, Touijer K. Analysis of clinical-pathological features and survival for patients under the age of 40 with renal cortical tumours. European Urology Supplements, Volume 5, Issue 2, April 2006, Page 107
13. Touijer K, **Iasonos A**, Mitra N, Cho E, Bochner B, Herr H, Dalbagni G, and Donat SM. Does Body Mass

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

Index (BMI) Affect the Quality and Morbidity of Radical Cystectomy for Bladder Cancer? Accepted for podium session AUA, San Antonio, TX, May 2005.

14. Black D, **Iasonos A**, Ahmed H, Chi DS, Barakat RR, Abu-Rustum NR. Venous thromboembolism and survival in ovarian, primary peritoneal and fallopian tube cancer patients. Presented at the 2006 Society Gynecologic Oncology.
15. Lewin SN, Magid CS, Soslow RA, **Iasonos A**, Linkov I, Barakat RR, Aghajanian CA, Dupont J. High AKT expression in epithelial ovarian cancer (EOC) correlates with poor clinical outcome which is not ameliorated by PTEN. Presented at the 2006 Society Gynecologic Oncology.
16. Lewin SN, **Iasonos A**, Tracy B, Hansen J, Kosarin K, Chou JF, Castiel M, Barakat RR, Offit K, Kauff ND. The Impact of Hormone Replacement Therapy on Post-Menopausal Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Presented at the 2006 Society Gynecologic Oncology.
17. Bajorin DF, Ostrovnaya I, **Iasonos A**, Milowsky M. I., Boyle M, Riches J. A nomogram predicting survival of patients (pts) with metastatic or unresectable urothelial cancer (UC) treated with cisplatin-based chemotherapy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5055
18. **Iasonos A**, Schrag D, Raj GV, Russo P, Panageas KS. Uncertainty around individualized predictions using nomograms: The concept of individualized prediction intervals. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 6526
19. Konner JA, Fallon K, Pezzuli S, **Iasonos A**, Sabbatini P, Hensley M, Chiang A, Tew W, Spriggs D, Aghajanian C. A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5523
20. Basch EM, **Iasonos A**, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Scher HI, Schrag D. Long-term toxicity monitoring via electronic patient reported outcomes in end-stage chemotherapy patients. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June Supplement), 2007: 9025
21. Gallagher DJ, Milowsky MI, Gerst SR, **Iasonos A**, Riches J, Boyle MG, Bajorin DF. Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5080
22. Abu-Rustum NR, **Iasonos A**, Zhou Q, Oke E, Soslow RA, Alektiar KM, Chi DS, Barakat RR. Is there a therapeutic benefit to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?" Presented as an invited paper at the 2007 American Gynecological and Obstetrical Society
23. Zivanovic O, Eisenhauer EL, Zhou Q, **Iasonos A**, Abu-Rustum NR, Sonoda Y, Levine DA, Brown CL, Barakat RR, Chi DS. A Cytorreductive outcomes in patients with stage IIIC epithelial ovarian, fallopian tube or primary peritoneal cancer and moderate to large volume ascites, SGO 2007 (San Diego,

CURRICULUM VITAE

ALEXIA E. IASONOS, Ph.D.

California, April 2007).

24. Zivanovic O, **Iasonos A**, Leitao MM, Zhou Q, Soslow RA, Juretzka MM, Chi DS, Brennan MF, Hensley ML. Stage-Specific Survival of Patients with Uterine Leiomyosarcoma: A Comparison of FIGO and AJCC Staging System, ASCO 2008 (Chicago, Illinois, May 2008) J Clin Oncol 26: 2008 (May 20 suppl; abstr 5554)
25. Zivanovic O, Alektiar KM, Sonoda Y, Zhou Q, **Iasonos A**, Tew WP, Diaz JP, Chi DS, Barakat RR, Abu-Rustum NR. Treatment Patterns of FIGO Stage IB2 Cervical Cancer: Radical Hysterectomy with Individualized Postoperative Therapy or Definitive Radiation Therapy with or without Chemotherapy, oral presentation at SGO Winter Meeting 2008 (Park City, Utah, February 2008)
26. Zivanovic O, **Iasonos A**, Leitao MM, Zhou Q, Soslow RA, Juretzka MM, Chi DS, Brennan MF, Hensley ML. Stage-Specific Survival of Patients with Uterine Leiomyosarcoma: A Comparison of FIGO and AJCC Staging System, plenary presentation at the 14th Annual Meeting of the Connective Tissue Oncology Society (November 2008, London, UK)
27. Zivanovic O, Sima CS, **Iasonos A**, Martinez AR, Pingle PR, Leitao MM, Sonoda Y, Abu-Rustum NR, Eisenhauer EL, Barakat RR, Chi DS. Upper Abdominal Disease Cephalad to the Greater Omentum and the Impact on Progression-Free Survival in Patients with Stage IIIC Ovarian Cancer, opening plenary presentation at SGO 2009 (San Antonio, Texas, February 2009)
28. **Iasonos A**, Riedel ER, Spriggs DR . Is the Continual Reassessment Method superior to the standard 3+3 dose escalation scheme? ASCO 2008. J Clin Oncol 26: 2008 (May 20 suppl; abstr 2559)
29. Gallagher DJ, Milowsky MI, Gerst SR, **Iasonos A**, Boyle MG, Trout A, Riches J, Bajorin DF. Final results of a phase II study of sunitinib in patients with relapsed or refractory urothelial carcinoma. 2008 ASCO. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5082)
30. **Iasonos A**, Riedel E. Is the Continual Reassessment Method a better Phase I Design? A comprehensive comparison with the standard 3+3 dose escalation scheme. ENAR, International Biometric Society 2008.
31. Abu-Rustum NR, Zhou Q, **Iasonos A**, Soslow R, Sabbatini P, Levine D, Alektiar K, Chi DS, Barakat RR. Does Clear Cell Endometrial Carcinoma Have a Similar Prognosis to Serous Endometrial Carcinoma? SGO 2008.
32. Spriggs DR, **Iasonos A.**, Sabbatini P., O'Cearbhaill R. E., Thaler H. T. Defining clinical and statistical improvement in consolidation single-arm trials in ovarian cancer. J Clin Oncol 28:15s, 2010 (suppl; abstr 5032).
33. **Iasonos A.**, Zohar S., O'Quigley J. Two-stage continual reassessment method that determines dose-escalation based on individual toxicity grades. Society of Clinical Trials 31st Annual Meeting 2010 (abstract P94).
34. **Iasonos A.** O'Quigley J. The impact of priors and skeletons in model based dose finding studies. 32nd Annual Meeting of International Society of Clinical Biostatistics. 2011.

35. **Iasonos A.**, Sabbatini P, Spriggs D, Thaler H, Defining clinical and statistical improvement in consolidation or maintenance single-arm trials in Oncology. Society of Clinical Trials. 2012
36. **Iasonos A.**, Emily Keung, Oliver Zivanovic, Rosanna Mancari, Michele Peiretti, Marisa Nucci, Suzanne George, Nicoletta Colombo, Silvestro Carinelli, Martee L. Hensley, Chandrajit P Raut. External validation of a nomogram predicting overall survival (OS) of women with uterine leiomyosarcoma (ULMS). American Society of Clinical Oncology. 2012
37. **Iasonos A.** O'Quigley J. Intermediary Grade Toxicities in Phase I Clinical Trials: How Much Information Is There? Joint Statistical Meeting. 2012

4. Poster or Contributed Oral Presentations:

1. **Iasonos A**, Zurbenko IG. An Evaluation Model for the Performance of a Company Relative to the Market. Proceedings of the Joint Statistical Meeting, 2001.
2. **Iasonos A**, Zurbenko I.G. The effect of missing data on linear filters. Proceedings of the Joint Statistical Meeting 2002.
3. **Iasonos A**, Chen T., Maniero A., Bogaerts J. QoL in Oncology: A Review of Several Models for the Area Under the Curve Analysis. Proceedings of the Joint Statistical Meeting 2003.
4. **Iasonos A**. Raj GV. Utility of pre-operative doppler ultrasonography in predicting histology of renal masses. Joint Statistical Meeting 2006.
5. **Iasonos A**, Schrag D, Raj GV, Russo P, Panageas KS. Uncertainty around individualized predictions using nomograms: The concept of individualized prediction intervals. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 6526.
6. **Iasonos A**, Wilton AS.; Riedel ER.; Seshan V. Is the Continual Reassessment Method a better Phase I design? A comprehensive comparison with the standard 3+3 dose escalation scheme. International Biometrics Society, ENAR 2008 Meeting.
7. **Iasonos A**, Riedel ER, Spriggs DR . Is the Continual Reassessment Method superior to the standard 3+3 dose escalation scheme? ASCO 2008. J Clin Oncol 26: (May 20 suppl; abstr 2559).
8. **Iasonos A.**, Zohar S., O'Quigley J. Two-stage continual reassessment method that determines dose-escalation based on individual toxicity grades. Society of Clinical Trials 31st Annual Meeting 2010 (abstract P94).
9. Spriggs DR, **Iasonos A.**, Sabbatini P., O'Cearbhaill R. E., Thaler H. T. Defining clinical and statistical improvement in consolidation single-arm trials in ovarian cancer. J Clin Oncol 28:15s, 2010 (suppl; abstr 5032).
10. **Iasonos A.**, O'Quigley J. The impact of priors and skeletons in model based dose finding studies. 32nd Annual Meeting of International Society of Clinical Biostatistics. 2011.

- 11. Iasonos A.,** Sabbatini P, Spriggs D, Thaler H, Defining clinical and statistical improvement in consolidation or maintenance single-arm trials in Oncology. Society of Clinical Trials. 2012
- 12. Iasonos A.,** Emily Keung, Oliver Zivanovic, Rosanna Mancari, Michele Peiretti, Marisa Nucci, Suzanne George, Nicoletta Colombo, Silvestro Carinelli, Martee L. Hensley, Chandrajit P Raut. External validation of a nomogram predicting overall survival (OS) of women with uterine leiomyosarcoma (ULMS). American Society of Clinical Oncology. 2012

Date: 10/6/2016

Alexia Iasonos, PhD